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Background: The efficacy and safety of olanzapine monotherapy are evaluated in Japanese patients from a large,
global study of bipolar depression.
Methods: This is an analysis of Japanese patients from a 6-week, global (Japan, China, Korea, Taiwan, and the
United States), randomized, double-blind, placebo-controlled, Phase 3 study of patients with a depressive episode
of bipolar I disorder. The primary outcome was baseline-to-endpoint change in the Montgomery-Åsberg
Depression Rating Scale (MADRS) total score. Secondary outcome measures included the Clinical Global
Impressions-Bipolar Version Severity of Illness Scale (CGI-BP), the 17-item Hamilton Depression Rating Scale (HAMD-
17) total score, the Young Mania Rating Scale (YMRS) total score, and rates of response (≥50% baseline-to-endpoint
reduction in MADRS total score), recovery, and remission.
Results: Of the 156 Japanese patients, 104 had been allocated to olanzapine and 52 to placebo. All results are
baseline-to-endpoint change. Compared to placebo, patients in the olanzapine group experienced greater
improvement in the primary outcome measure, MADRS total score (−14.9 vs. −10.7; p = .01). They also had greater
reductions in the following secondary measures: CGI-BP Depression (−1.41 vs. -0.89; p = .008), CGI-BP Bipolar
(−1.31 vs. −0.83; p = .01), HAMD-17 (−11.7 vs. −7.9; p < .01), and YMRS (-0.32 vs. 0.34; p = .03). Differences in rates of
response, recovery, and remission were not statistically significant. A greater proportion of olanzapine-treated
patients reported treatment-emergent adverse events (87.5% vs. 59.6%; p < .001). Patients treated with olanzapine
had greater increases in weight (p < .001) and fasting total cholesterol (p = .008); fasting triglycerides (p = .02), and
fasting low-density lipoprotein (p = .01). There was a greater reduction in fasting high-density lipoprotein in
olanzapine-treated patients (p = .01). Compared with placebo-group patients, more olanzapine-group patients
shifted from borderline to high cholesterol (25.0% vs. 0.0%; p = .007) and had clinically significant weight gain
(≥7% body weight) (20.2% vs. 1.9%; p = .001).
Conclusions: Results of this analysis support the efficacy and tolerability of olanzapine for the treatment of bipolar
depression in Japanese patients. Results in this population were consistent with those seen in the more ethnically
diverse parent study. In making treatment decisions for individual patients, clinicians should carefully consider the
risks and benefits of olanzapine treatment.
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Bipolar disorder is a devastating condition with a global
lifetime prevalence of 2.4% [1] that is characterized by
episodic alterations in energy level, cognition, and mood
consistent with mania, depression, or mixed states of
manic and depressive symptoms. Multiple agents have
shown efficacy in the treatment of bipolar mania includ-
ing lithium, valproate, and all currently available atypical
antipsychotics [2-4]. When managing bipolar depression,
a tricyclic antidepressant, norepinephrine-dopaminergic
reuptake inhibitor, or selective serotonin reuptake inhibi-
tor is frequently combined with a mood-stabilizing agent
[5,6], though the efficacy and safety of this strategy is
not well-established.
More recently, atypical antipsychotics have been used
as monotherapy for bipolar depression. Efficacy was
demonstrated in 2 randomized, placebo-controlled trials
of quetiapine for treatment of depressive episodes in
patients with bipolar I and bipolar II disorder [7,8]. In
contrast, efficacy was not shown in randomized,
placebo-controlled studies of aripiprazole [9-11] and
ziprasidone [12] as monotherapy for acute bipolar
depression.
In a single 8-week, double-blind protocol comparing
olanzapine, olanzapine-fluoxetine, and placebo which
was conducted as 2 contemporaneous, identical studies,
both treatments were more effective than placebo when
study results were combined [13]. When analyzed separ-
ately, however, a significant advantage over placebo was
seen with combination therapy in both studies, while
olanzapine as monotherapy was more effective than pla-
cebo in only 1 of the 2 studies (Data on File, Eli Lilly
and Company).
To further evaluate the effectiveness of olanzapine
monotherapy for the treatment of depressive episodes in
bipolar I disorder, a large, international, double-blind,
placebo-controlled trial was undertaken [14]. After
6 weeks of treatment, patients allocated to olanzapine
had significantly greater baseline-to-endpoint improve-
ment in the Montgomery-Åsberg Depression Rating
Scale (MADRS) [15] total score compared with patients
allocated to placebo (−13.8 vs. −11.7; p = .02). Likewise,
with response defined a priori as a ≥50% reduction in
MADRS total score at endpoint, the olanzapine group
had a significantly greater response than the placebo
group (52.5% vs. 43.3%, p = .0498).
Prior to 2012, there were no medication options with
well-established evidence approved in Japan for treat-
ment of bipolar depression. Though compelling data
existed for treatment of bipolar depression in Western
populations, it was unclear whether these findings would
hold true for a cohort of Japanese patients. The
olanzapine monotherapy trial described above included
a large cohort of Japanese patients and, to ourknowledge, was the first double-blind, placebo-
controlled trial to do so. Based on the results of this
trial, Japan became the first country in the world to
approve olanzapine monotherapy for treatment of bipo-
lar depression. Though olanzapine monotherapy has
been used for the treatment of this condition in Japan,
limited data have been published. Therefore, we ana-
lyzed efficacy and safety data from Japanese patients
who were enrolled in the larger study described above,
so that clinicians who care for Japanese patients will
have a more comprehensive understanding of its treat-
ment profile in this population.
Methods
Patients
Patients from the parent study were men and women in-
patients and outpatients, age 18 to 64 years. They were
recruited in Japan, China, Taiwan, Korea, and the United
States and met diagnostic criteria for a major depressive
episode and for bipolar I disorder (Diagnostic and Statis-
tical Manual of Mental Disorders, fourth edition, text
revision). Only patients who were recruited in Japan
were included in this subanalysis. At the time of
randomization, all patients were in a depressive episode
that had lasted 90 days or less, and was defined by a
17-item Hamilton Depression Rating Scale (HAMD-17)
[16] total score ≥18. None were actively in a manic epi-
sode, defined as having a Young Mania Rating Scale
(YMRS) [17] total score ≤8. All patients had a history of
at least 1 manic or mixed episode in the previous 6 years.
Exclusion criteria included unstable medical illness; his-
tory of diabetes, hemoglobin A1c ≥6.5% or blood glucose
level indicative of diabetes; history of serious psychiatric
illness other than bipolar depression; current rapid cyc-
ling mood disturbance; recent use of clozapine, depot
antipsychotics, or central nervous system medications
other than mood stabilizers; and recent history of sub-
stance dependence.
Study design
This was a 6-week, randomized, double-blind, placebo-
controlled, Phase 3 study of olanzapine as monotherapy
for treatment of patients with bipolar I disorder who
were acutely depressed. The study was approved by the
relevant institutional ethics committee at each center
and was conducted in compliance with the Declaration
of Helsinki. Names of the specific review boards can be
found in the Ethics Approval section at the end of this
manuscript. Following a complete description of the
study and prior to initiation of any study drug or pro-
cedure, written informed consent was obtained from the
patient. Patients who met all inclusion criteria and no
exclusion criteria were then randomly assigned in a 2:1
ratio to olanzapine (5-20 mg/day at the discretion of the
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weekly through Week 6. Data collected beyond the acute
phase portion of the study were not included in this
analysis.
Assessment measures
Efficacy was assessed using change from baseline to end-
point in total scores of the following assessment tools:
 MADRS: A clinician-administered interview
regarding symptoms of depression in the previous
week, and consisting of 10 items, each scored from
0 to 6 in increasing order of severity.
 Clinical Global Impressions-Bipolar Version Severity
of Illness Scale (CGI-BP) [18]: A clinician rating of
global symptom severity at the time of assessment
relative to other patients with bipolar depression.
Symptom severity is scored from 1 to 7, where 1
equals normal and 7 equals extremely ill.
 HAMD-17: A 17-item, multiple-choice
questionnaire in which based on interview and
observation, the clinician must choose the best
possible response regarding a patient’s severity of
depression. Each question has between 3 and 5
possible responses, and total scores range from 0 to
52, where higher values indicate greater severity.
The potential to induce manic symptoms was assessed
using the following tool:
 YMRS: An 11-item, multiple-choice questionnaire
regarding symptoms of mania. Rated by the
clinician, the YMRS total score ranges from 0 to 60,
where higher scores indicate greater severity.
Rates of response, remission, and recovery were
assessed. Response was defined as a baseline-to-endpoint
reduction of ≥50% in MADRS total score, and recovery
was defined as a score ≤12 in the MADRS total score for
at least 4 weeks and completion of the 6-week study. Re-
mission was a priori defined as a MADRS total score
≤12 (called partial remission in this manuscript), and
was defined post hoc as a MADRS total score ≤8 (as
recommended by the International Society of Bipolar
Disorder [ISBD], called full remission in this manuscript)
[19]. Additionally, study discontinuation and emergence
of mania were assessed.
Safety evaluation
All adverse events occurring during the course of the
study were documented and vital signs and weight were
assessed at each visit. Electrocardiograms and laboratory
analytes, including measures of fasting glucose and
lipids, were assessed at baseline and endpoint. Patientswere screened for the emergence of extrapyramidal
symptoms at every visit using the Drug-induced Extra-
pyramidal Symptoms Scale [20] (DIEPSS). At every visit,
patients were also assessed for suicidality using the Mini
International Neuropsychiatric Interview [21] (MINI)
and for the emergence of mania (YMRS total score <8).
Statistical analysis
Analyses were based on the intention-to-treat set of Jap-
anese patients. All tests of treatment effect were
conducted at a 2-sided significance level of 0.05, and no
adjustments were made for multiple comparisons. Con-
tinuous data were assessed using analysis of covariance
models with type III sums of squares with a term for
treatment and with the baseline measurement value in-
cluded as a covariate. For continuous data where a base-
line measurement was not applicable, analysis of
variance (ANOVA) models were used, with a term for
treatment. The primary analysis of change from baseline
to endpoint in MADRS total score was based on last-
observation-carried-forward (LOCF) change. Post hoc
analyses of MADRS and the MADRS-6 subscale, which
focuses on the “core” symptoms of depression (as
assessed by the MADRS items: Apparent Sadness,
Reported Sadness, Inner Tension, Lassitude, Inability to
Feel, and Pessimistic Thoughts) [22,23] were preformed.
As a sensitivity analysis, observed-case ANOVA and
mixed-effects model repeated measures (MMRM) were
used to assess changes in MADRS total score. For ana-
lyses of proportions, the Fisher exact test was used.
Results
Patient disposition
Of the 514 patients randomly allocated to treatment in
the parent study, 156 were Japanese. As shown in
Figure 1, the acute phase of the study was completed by
86 of the 104 Japanese patients randomized to
olanzapine (82.7%) and 41 of the 52 Japanese patients
randomized to placebo (78.8%; p = .66). Patients treated
with olanzapine received a mean (standard deviation,
[SD]) daily dose of 9.98 (3.14) mg.
At baseline, treatment groups did not differ with
regard to gender distribution or the number of prior
episodes of mania, depression, or mixed symptoms. Pa-
tients in the olanzapine group were significantly older
(40.0 [SD 11.0] years vs. 36.3 [SD 9.5] years; p = .04), had
been older at the time of illness onset (33.1 [SD 10.9]
years vs. 29.1 [SD 8.8] years; p = .02), and weighed less at
baseline (59.0 [SD 12.4] kg vs. 64.0 [SD 12.1] kg; p = .02)
than those in the placebo group. There were no
between-group differences for baseline MADRS total
score, HAMD-17 total score, YMRS total score, or any
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Figure 1 Patient flow diagram.
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Baseline-to-endpoint (Week 6) change in MADRS total
score was statistically different between groups, with the
olanzapine group having greater least-squares (LS) mean
score reductions compared with the placebo group
(−14.9 [standard error; SE 1.0] vs. −10.7 [SE 1.4];Table 1 Baseline demographics, illness history, and
baseline illness severity
Placebo Olanzapine
(N = 52) (N = 104)
Female gender, n (%) 27 (51.9) 63 (60.6)
Age in years, mean (SD) 36.3 (9.5) 40.0 (11.0)
Age in years at onset of BD, mean (SD) 29.1 (8.8) 33.1 (10.9)
Prior episodes, mean (SD)
Manic 3.02 (3.07) 3.32 (4.46)
Depressive 3.77 (3.35) 4.54 (5.69)
Mixed 0.23 (0.70) 0.13 (0.48)
Weight in kg, mean (SD) 64.02 (12.14) 59.04 (12.35)
Illness severity scores, mean (SD)
MADRS total 28.62 (8.01) 29.00 (6.15)
YMRS total 0.85 (1.32) 0.88 (1.32)
HAMD-17 total 22.69 (4.08) 23.10 (3.78)
CGI-BP
Depression 4.23 (0.73) 4.35 (0.75)
Mania 1.02 (0.14) 1.03 (0.17)
Bipolar 4.10 (0.87) 4.17 (0.86)
Abbreviations: BD = bipolar disorder; CGI-BP = Clinical Global Impressions-
Bipolar Version Severity of Illness; HAMD-17 = Hamilton Depression Rating
Scale-17 items; MADRS =Montgomery-Åsberg Depression Rating Scale;
SD = standard deviation; YMRS = Young Mania Rating Scale.p = .01). The effect size for the primary outcome was
0.42 (95% confidence interval 0.09, 0.76). Visit-wise
changes in LS mean MADRS total score are shown in
Figure 2. The olanzapine group had a significantly
greater reduction in score than the placebo group, be-
ginning as early as Week 2 (−10.4 [SE 0.8] vs. −7.6 [SE
1.1]; p = .04). Sensitivity analyses using observed case
(Week 2: -11.10 vs. -7.31, p = .006; Week 6: -16.34 vs. -
12.95, p = .04) and MMRM (Week 2: -11.10 vs. -7.38,
p = .006; Week 6: -16.36 vs. -12.91, p = .046) methodolo-
gies yielded similar results (Additional file 1: Figures S1
and Additional file 2: Figure S2).
Secondary efficacy outcomes
As shown in Table 2, efficacy in treating bipolar depres-
sion was further supported by significantly greater
baseline-to-endpoint improvement in the HAMD-17
total score for the olanzapine group than for the placebo
group (−11.7 [SE 0.74] vs. −7.9 [SE 1.04]; p = .004).
Olanzapine treatment was superior to placebo in
clinician-based assessments of global illness severity.
Baseline-to-endpoint improvement was significantly
greater for both the CGI-BP Depression scale (−1.4 [SE
0.11] vs. −0.9 [SE 0.16]; p = .008) and the CGI-BP Bipo-
lar scale (−1.3 [SE 0.11] vs. −0.8 [SE 0.15]; p = .01).
Patients had a low level of mania symptoms at baseline,
and the mean change at endpoint in YMRS total scores
improved for the olanzapine group and worsened for the
placebo group (−0.32 [SE 0.17] vs. 0.34 [SE 0.24];
p = .03). No patients in the olanzapine group or in the
placebo group met criteria for the emergence of mania
(Table 2).
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Figure 2 Visit-wise change from baseline in LS mean MADRS total score (Last observation carried forward methodology). Abbreviations:
MADRS =Montgomery-Åsberg Depression Rating Scale; LS mean = least squares mean.
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Changes in baseline-to-endpoint scores on individual
items of the MADRS scale and the MADRS-6 subscale
are shown in Table 3. Both LOCF and MMRM analyses
are represented. In the comparison between olanzapine
and placebo groups, patients in the olanzapine group
showed significantly greater improvement in Inner Ten-
sion, Reduced Sleep, Reduced Appetite, and Pessimistic
Thoughts by LOCF analysis. By MMRM analysis, the
olanzapine group showed significantly greater improve-
ment than the placebo group in these 4 variables as well
as in Reported Sadness and Inability to Feel. Likewise,
the olanzapine group showed significantly greater
improvement than the placebo group in MADRS-6
subscale scores by both LOCF and MMRM analyses.
Response, remission, and recovery
There were no significant differences between treatment





(n = 52) (n = 104)
LS Mean (SE) LS Mean (SE)
CGI-BP
Depression −0.89 (0.16) −1.41 (0.11) .008
Mania 0.03 (0.04) 0.01 (0.03) .68
Bipolar −0.83 (0.15) −1.31 (0.11) .01
HAMD-17 total −7.88 (1.04) −11.66 (0.74) .004
YMRS total 0.34 (0.24) −0.32 (0.17) .03
Abbreviations: CGI-BP = Clinical Global Impressions-Bipolar Version Severity of
Illness; HAMD-17 = Hamilton Depression Rating Scale-17 items; LS mean = least
squares mean; SE = standard error; YMRS = Young Mania Rating Scale.However, rates of symptomatic response were numeric-
ally greater for the olanzapine group compared with
those for the placebo group (54.8% vs. 40.4%, p = .13;
Table 4). When analyzed with the post hoc definition of
MADRS total score ≤8, rates of full remission and recov-
ery were numerically higher for olanzapine. Rates of par-
tial remission, when defined as a MADRS total score
≤12 at any point in time, were slightly higher for the pla-
cebo group (Table 4).
Safety measures
Safety data were consistent with those seen in the parent
study and with the known safety profile of olanzapine.
There were no deaths, and one serious adverse event,
hypokalemic periodic paralysis in a patient in the
olanzapine group. The rate of discontinuation due to an
adverse event did not differ between groups (9.6% for
olanzapine and 7.7% for placebo; p = .78). Compared
with the placebo group, the olanzapine group had
significantly higher rates of treatment-emergent adverse
events (87.5% vs. 59.6%; p < .001), over half of
which were possibly related to study drug (64.4%).
Treatment-emergent adverse events occurring in ≥5% of
olanza-pine-treated patients were somnolence (38.5%),
weight increase (28.8%), increased appetite (16.3%),
nasopharyngitis (14.4%), constipation and thirst (both
7.7%), malaise (6.7%), and elevations of alanine aminotrans-
ferase and aspartate aminotransferase (both 5.8%).
After 6 weeks of treatment, patients in the olanzapine
group had significantly greater weight gain than patients
in the placebo group (2.12 [SE 0.21] kg vs. −0.36 [SE
0.29] kg; p < .001). Also, clinically significant weight gain
(≥7% above baseline) occurred more commonly in the
Table 3 Baseline-to-endpoint change in itemized LS Mean MADRS scores
LOCF analysis MMRM analysis
Baseline Endpoint p Valuea Endpoint p Valueb









Apparent Sadness PBO 52 3.12 (1.06) −1.42 (0.19) <.001 .36 43 −1.47 (0.19) <.001 .16
OLZ 104 3.23 (1.10) −1.63 (0.13) <.001 87 −1.80 (0.13) <.001
Reported Sadness PBO 52 3.35 (1.23) −1.56 (0.20) <.001 .10 43 −1.60 (0.21) <.001 .03
OLZ 104 3.57 (1.06) −1.95 (0.14) <.001 87 −2.15 (0.15) <.001
Inner Tension PBO 52 2.71 (1.23) −0.73 (0.16) <.001 <.001 43 −0.78 (0.16) <.001 <.001
OLZ 104 2.70 (1.09) −1.43 (0.11) <.001 87 −1.53 (0.12) <.001
Reduced Sleep PBO 52 3.02 (1.63) −0.75 (0.22) <.001 <.001 43 −1.01 (0.22) <.001 .001
OLZ 104 2.88 (1.63) −1.83 (0.15) <.001 87 −1.91 (0.16) <.001
Reduced Appetite PBO 52 1.79 (1.70) −0.78 (0.16) <.001 .003 43 −0.91 (0.16) <.001 .004
OLZ 104 1.77 (1.52) −1.35 (0.11) <.001 87 −1.51 (0.12) <.001
Concentration Difficulties PBO 52 3.65 (1.23) −1.30 (0.21) <.001 .75 43 −1.46 (0.22) <.001 .78
OLZ 104 3.67 (1.08) −1.38 (0.15) <.001 87 −1.53 (0.16) <.001
Lassitude PBO 52 3.10 (1.09) −1.22 (0.19) <.001 .32 43 −1.33 (0.20) <.001 .37
OLZ 104 3.23 (1.10) −1.45 (0.13) <.001 87 −1.56 (0.14) <.001
Inability to Feel PBO 52 3.29 (1.18) −1.20 (0.20) <.001 .06 43 −1.24 (0.22) <.001 .03
OLZ 104 3.43 (0.91) −1.66 (0.14) <.001 87 −1.82 (0.15) <.001
Pessimistic Thoughts PBO 52 3.08 (1.08) −1.05 (0.19) <.001 .03 43 −1.04 (0.20) <.001 .01
OLZ 104 3.10 (1.02) −1.54 (0.13) <.001 87 −1.66 (0.14) <.001
Suicidal Thoughts PBO 52 1.52 (1.0) −0.68 (0.13) <.001 .87 43 −0.80 (0.13) <.001 .95
OLZ 104 1.41 (0.82) −0.71 (0.09) <.001 87 −0.79 (0.09) <.001
MADRS-6c Subscale PBO 52 18.63 (5.02) −7.16 (0.94) <.001 .03 43 −7.25 (0.99) <.001 .008
OLZ 104 19.26 (3.88) −9.67 (0.66) <.001 87 −10.54 (0.70) <.001
Abbreviations: LOCF = last observation carried forward; LS mean = least squares mean; MADRS =Montgomery-Åsberg Depression Rating Scale; MMRM =mixed-
effects model repeated measures; OLZ = olanzapine group; PBO = placebo group; SD = standard deviation; SE = standard error.
a within treatment p values are from t-tests on LS Mean change; p values and LS Mean for change from baseline are from analysis of covariance model: change =
treatment + baseline + geographic region (Type III sums of squares).
b within treatment p values are from t-tests on LS Mean change; p values are from Type III sums of squares and Kenward-Roger approximation as denominator
degrees of freedom; MMRM analysis: change = treatment + baseline + geographic region + visit + treatment * visit.
c MADRS-6 subscale contains 6 individual MADRS items: Apparent Sadness, Reported Sadness, Inner Tension, Lassitude, Inability to Feel, and Pessimistic Thoughts,
considered to be “core” depressive symptoms.
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end of the study, serum cholesterol (10.06 mg/dL
vs. −0.96 mg/dL; p = .008) triglycerides (30.67 mg/dL
vs. −4.17 mg/dL; p = .02), and LDL (8.78 mg/dL
vs. -1.06 mg/dL, p = .01) had increased significantly more
in the olanzapine group than in the placebo group.
Compared to patients in the placebo group, serum
HDL cholesterol had decreased significantly more
in the olanzapine-treated group (-2.99 mg/dL vs.
1.10 mg/dL, p = .01).
Based on criteria established by the National Choles-
terol Education Program for assessing lipid changes, a
categorical change with potential clinical significance oc-
curred with greater frequency in the olanzapine group
than in the placebo group. Specifically, the percentage of
patients who shifted from borderline to high fasting totalcholesterol was significantly greater in the olanzapine
group (0% vs. 25%, p = .007) (Table 5). Using the
American Diabetes Association criteria for assessment of
abnormal blood glucose levels, no significant differences
between treatment groups were observed for categorical
changes in blood glucose levels (Table 5).
There were no significant differences between groups
in the proportion of patients with potentially clinically
significant changes in vital signs and no clinically signifi-
cant treatment-emergent electrocardiographic changes.
Compared with patients allocated to placebo, those
allocated to olanzapine had small but statistically greater
baseline-to-endpoint decreases in hemoglobin (-0.17
[0.42] g/L vs. −0.01 [SD 0.45] g/L; p = .04), total bilirubin
(−1.07 [3.80] μmol/L vs. 0.71 [4.10] μmol/L; p = .02), and
direct bilirubin (−0.33 [0.83] μmol/L vs. 0.15 [0.85]
Table 4 Response, remission, recovery, and study
discontinuation
Placebo Olanzapine
p Value(n = 52) (n = 104)
n (%) n (%)
Response 21 (40.4) 57 (54.8) .13
Partial remission (MADRS ≤12) 29 (55.8) 56 (53.8) .87
Full remission (MADRS ≤8) 18 (34.6) 45 (43.3) .39
Recovery 5 (9.6) 15 (14.4) .46
Study discontinuations
Total 11 (21.2) 18 (17.3) .66
Due to adverse events 4 (7.7) 10 (9.6) .78
Due to lack of efficacy 1 (1.9) 0 (0.0) .33
Lost to follow-up 0 (0.0) 1 (1.0) 1.00
Abbreviations: MADRS =Montgomery-Åsberg Depression Rating Scale.
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creases in gamma-glutamyltransferase (1.66 [28.8] μkat/
L vs. −2.08 [12.9] μkat/L; p = .001) and prolactin (11.15
[19.69] pmol/L vs. −4.00 [25.14] pmol/L; p < .001) were
noted for the olanzapine group compared to placebo.
Baseline-to-endpoint change in hemoglobin A1c did not
differ between groups.
An assessment of suicidality (MINI Section C) re-
vealed no significant difference between groups. The
maximum increase from baseline in DIEPSS score was
0.33 (SD 0.76) in the olanzapine group (p < .001) and
0.19 (SD 0.56) in the placebo group (p = .03), with no
significant difference between groups (p = .37).
Discussion
The results seen with olanzapine monotherapy in
Japanese patients with bipolar depression were consist-
ent with those seen in the global parent study from
which data for this subpopulation analysis were taken
[14], and also with results from a prior study in which
olanzapine monotherapy proved superior to placebo in
reducing depressive symptoms in non-Asian patients
with bipolar disorder experiencing an acute depressive
episode [24]. Improvements in depressive symptoms
were noted using multiple assessment tools (MADRS,
HAMD-17, and CGI-BP).
Greater efficacy with olanzapine than with placebo
was noted on individual items included in the MADRS.
Specifically, patients in the olanzapine group reported
less inner tension, less sleep reduction, better appetite,
and less pessimism. Treatment effects appeared espe-
cially strong for the Reduced Sleep and Reduced Appe-
tite MADRS items, and these findings may have clinical
impact related to both safety and efficacy. Improvement
of core symptoms of depression as assessed by the
MADRS-6 subscale was significantly greater during
treatment with olanzapine compared with placebo whenanalyzed with LOCF and MMRM methodologies,
suggesting that olanzapine has an effect on the core
symptoms of depression.
Although statistically significant differences in out-
come measures were found between olanzapine and
placebo, the differences were numerically small. In
addition, the effect size demonstrated by olanzapine
monotherapy in this population was modest. Although
this could be indicative of a modest effect of the active
drug, it may also have been influenced by a relatively
strong placebo response. Increased placebo response is a
phenomenon which has been noted in different areas of
psychopharmacology in recent years [25,26]. Also, it is
important to appreciate that bipolar disorder is particu-
larly difficult to manage, and very few treatments have
regulatory approval for treatment of bipolar depression.
Therefore, even a modest effect size may be of clinical
relevance to patients, although treatment-emergent ad-
verse events need to be taken into consideration as well.
There were no significant treatment effects for rates of
response, recovery, or remission. However, these rates
represented dichotomous outcomes which, in some
cases, were quite severe in their definition. This may
have rendered possible differences over 6 weeks between
groups difficult to detect. Also, these assessments may
have been affected by the relatively small sample size of
the subpopulation included in this analysis. It is interest-
ing to note that the remission criterion defined a priori
(MADRS total score ≤12) yielded a very high rate of
remission in the placebo arm. A stricter criterion like
the one recommended by ISBD (MADRS total score ≤8)
may be preferable for signal detection in placebo-
controlled clinical trials.
Japanese patients treated with olanzapine monother-
apy in this study experienced no increase in manic
symptoms; rather, mean total scores on the YMRS actu-
ally improved compared with those for patients treated
with placebo. This result suggests that Japanese patients
with bipolar depression who are experiencing a depres-
sive episode may be able to be treated with olanzapine
without increasing the risk of treatment-emergent
mania. More importantly, this result suggests that symp-
toms of the opposite pole (mixed), a feature which is
common in bipolar depression, improve with the use of
olanzapine. The clinical importance of this finding was
highlighted by the results of a recent study in which pa-
tients with bipolar disorder who exhibited more manic
and hypomanic symptoms had less response to treatment
than patients who had fewer of these symptoms [27].
The safety profile of olanzapine in this 6-week trial
was similar to that seen in the parent study [14] from
which these data were taken, and which had a more eth-
nically diverse patient population. Likewise, changes in
weight and lipids were consistent with the known safety
Table 5 Absolute and categorical changes in weight, total cholesterol, triglycerides, LDL, HDL, and glucose
Placebo Olanzapine
p Valuen LS mean (SE) n LS mean (SE)
Weight gain, kg 52 −0.36 (0.29) 104 +2.12 (0.21) <.001
n/N (%) n/N (%)
Patients with significant weight gain (≥7% body weight) 1/52 (1.9) 21/104 (20.2) .001
n LS mean (SE) n LS mean (SE)
Baseline-to-endpoint change in fasting laboratory values
Cholesterol, mg/dL 52 −0.96 (3.37) 104 +10.06 (2.38) .008
Triglycerides, mg/dL 52 −4.17 (12.31) 104 +30.67 (8.68) .02
LDL, mg/dL 51 −1.06 (3.07) 103 +8.78 (2.16) .01
HDL, mg/dL 52 +1.10 (1.27) 104 −2.99 (0.90) .01
Glucose, mg/dL 51 −1.02 (1.11) 100 + 1.01 (0.79) .14
n/N (%) n/N (%)
Patients with categorical shifts in fasting cholesterol values
Normal to borderline 2/17 (11.8) 13/39 (33.3) .11
Normal to high 0/17 (0.0) 1/39 (2.6) 1.00
Borderline to high 0/25 (0.0) 13/52 (25.0) .007
Patients with categorical shifts in fasting triglyceride values
Normal to borderline 3/37 (8.1) 5/82 (6.1) .70
Normal to high 1/37 (2.7) 9/82 (11.0) .17
Normal to extremely high 0/37 (0.0) 0/82 (0.0) –
Borderline to high 1/9 (11.1) 3/12 (25.0) .60
Borderline to extremely high 0/9 (0.0) 0/12 (0.0) –
Patients with categorical shifts in fasting LDL cholesterol values
Normal to borderline 4/9 (44.4) 11/26 (42.3) >.99
Normal to high 0/9 (0.0) 0/26 (0.0) –
Borderline to high 0/34 (0.0) 6/68 (8.8) .18
Patients with categorical shifts in fasting HDL cholesterol values
Normal to low 0/46 (0.0) 8/97 (8.2) .05
Patients with categorical shifts in fasting glucose values
Normal to impaired 5/32 (15.6) 9/72 (12.5) .76
Impaired to high 0/18 (0.0) 2/28 (7.1) .51
Normal/impaired to high 0/50 (0.0) 3/100 (3.0) .55
Normal to high 0/32 (0.0) 1/72 (1.4) 1.00
Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; LS mean = least squares mean; SE = standard error.
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in patients with bipolar depression in this population
(+2.12 kg) than the weight gain observed in an earlier
6-week study of olanzapine for Japanese patients with
bipolar mania [27] (+1.22 kg).
The primary limitation of this analysis of data from a
Japanese subset of patients from a larger study was that
it was an exploratory analysis with no adjustment for
multiplicity. The study had fewer patients from which to
draw conclusions to address questions of interest. For
example, sample size may have been too small to reveal
significant differences for dichotomous outcomes such
as response and remission. Finally, the results presented
here are limited to Japanese patients, age 18 to 64 years.Conclusions
Results of this analysis support the efficacy and tolerabil-
ity of olanzapine in the treatment of Japanese patients
with bipolar depression. Results in the Japanese popula-
tion were consistent with the more ethnically diverse
parent study. In making treatment decisions for individ-
ual patients, clinicians should carefully consider the risks
and benefits of olanzapine treatment.
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